Jump to content

Intas Biopharmaceuticals

Add links
From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by 2405:205:c924:9095::1245:e0a4 (talk) at 03:16, 14 September 2018. The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Intas Pharmaceuticals - Biologics Business Unit
Company typeLimited
IndustryBiotechnology
Founded1984
HeadquartersAhmedabad, India
ProductsNeukine® (GCSF), Erykine® (EPO), Intalfa® (IFN), Pegasta® (Peg GCSF), Terifrac® (Teriparatide), Mabtas® (Rituximab), Folisurge® (FSH)
Number of employees
300-350 (2013)
Websitehttp://www.intaspharma.com/

The Biologics Business Unit (BU) of Intas Pharmaceuticals Limited was formerly an independent biotechnology company and was known as Intas Biopharmaceuticals Ltd. Intas Pharmaceuticals limited is an Indian company headquartered in Ahmedabad, India. The Biologics BU is located in Moraiya, Ahmedabad and is one of the leading biosimilar product manufacturers in Asia.

The Biologics BU of Intas Pharmaceuticals has biopharmaceutical operations with R&D facility and an EU-GMP certified bio-pharmaceutical manufacturing facility.[1]

History

Intas Biopharmaceuticals Limited was set up in year 1980, as an independent biotechnology division of Intas Pharmaceuticals Ltd., a mid-sized generic formulation manufacturer located in Ahmedabad, India. The BU was merged with the parent company Intas Pharmaceuticals Limited in the year 2013.

Corporate Headquarters and Production site of Intas Biopharmaceuticals Ltd.

The company faced EU-GMP (Good Manufacturing Practice) audit in December 2006, to seek approval of clinical trial of its biosimilar Filgrastim in Europe and was certified as EU-GMP compliant in April 2007, becoming the first company in India to receive such certification for biologics facility.

Apart from EU-GMP certification, the company also has approvals from MCC South Africa, Gulf Cooperation Council (GCC), Syria, Yemen, Belarus and several other national health authorities for its manufacturing facility and products.

Intas Biosimilar development timeline
MabTas is Rituximab biosimilar of Intas
Intas manufactured Filgrastim registered in EU

References

  1. ^ "Intas mfg unit gets EU-GMP certification". The Economic Times. 13 June 2007.

News Articles

  • [1] Intas Biopharma to market PEMETREXED in India : February 2009
  • [2] Apotex and Intas Biopharmaceuticals extend their collaborative development of biosimilars to include Peg filgrastim : January 2009
  • [3] Intas Biopharma to Market Lung Cancer Drug GEFITINIB in India : May 2008
  • [4] Biosimilar G-CSF: Cooperation on Three Continents : April 2008
  • [5] Paragon of success : June 2008
  • [6] Intas Biopharma launches new Sales Divisions in India : March 2008
  • [7] Intas Pharmaceuticals Limited - Gets the 1st Biosimilar Approval for EU : June 2014
  • [8] Intas Pharma launches its first biosimilar product in Europe : Feb 2015
  • [9] Ahmedabad-based Intas Pharma launches biosimilar in EU : Feb 2015
  • [10] Intas Pharmaceuticals Becomes the First Indian Company to Launch a Biosimilar in the EU : Feb 2015
  • [11] Intas Pharmaceuticals launches biosimilar in Europe : Feb 2015
Retrieved from "https://en.wikipedia.org/w/index.php?title=Intas_Biopharmaceuticals&oldid=859446749"